Skip to main content

Quest Diagnostics Value Stock - Dividend - Research Selection

Quest diagnostics

ISIN: US74834L1008 , WKN: 904533

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company\'s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Here's Why You Should Add NVST Stock to Your Portfolio Right Now

2026-01-07
Envista's global expansion, bolt-on acquisitions, and strong balance sheet support growth, even as currency swings pressure sales.

IDEXX Stock Up 64.7% in a Year: What's Driving the Growth?

2026-01-07
IDXX shares surge 64.7% in a year as CAG Diagnostics momentum, strong retention and expanding software adoption fuel growth across regions.

PracticeQ Partners With Fullscript to Streamline Lab Testing and Improve Patient Care

2026-01-06
SAN DIEGO, January 06, 2026--PracticeQ and Fullscript partner to simplify lab ordering and results management, helping providers deliver faster, more connected care.

Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium

2026-01-06
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics.

Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead?

2026-01-06
HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.

Should Labcorp Stock Stay in Your Portfolio Right Now?

2026-01-06
LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.

Assessing Quest Diagnostics (DGX) Valuation After Recent Share Price Momentum And Perceived Undervaluation

2026-01-06
Quest Diagnostics (DGX) has been drawing attention after recent trading left the shares with a negative move over the past month and past 3 months, prompting investors to reassess the company’s fundamentals and valuation. See our latest analysis for Quest Diagnostics. At a share price of US$173.49, Quest Diagnostics has seen short term share price pressure, with a 30 day share price return of 4.94% and a 90 day share price return of 4.09%. This comes even as its 1 year total shareholder...

Corewell Health and Quest Diagnostics Complete Laboratory Joint Venture Transaction in Michigan

2026-01-05
Corewell Health and Quest Diagnostics (NYSE: DGX) today announced the completion of the previously announced transaction to establish a laboratory services joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

What You Need To Know Ahead of Quest Diagnostics' Earnings Release

2026-01-05
Quest Diagnostics is expected to unveil its fourth-quarter results soon, and analysts expect a single-digit growth in earnings.

Is it the Right Time to Add Insulet Stock to Your Portfolio?

2026-01-02
PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.